When was Relmada Therapeutics, Inc founded?
Relmada Therapeutics, Inc was founded in 2004.
Where are Relmada Therapeutics, Inc headquarters?
Relmada Therapeutics, Inc headquarters are in 2222 Ponce De Leon Blvd, Floor 3, Coral Gables, Florida 33134, US.
How many employees does Relmada Therapeutics, Inc have?
Relmada Therapeutics, Inc has 33 employees.
What sector does Relmada Therapeutics, Inc operate in?
Relmada Therapeutics, Inc is in Pharmaceutical Manufacturing sector.
What does Relmada Therapeutics, Inc Do ?
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment and monotherapy for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules. REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of MDD in adjunctive and monotherapy Phase 3 studies. The ongoing RELIANCE Phase 3 Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated rapid, robust, and sustained antidepressant effects with statistically significant improvements compared to placebo in tested measures of depression. The Phase 2 study also showed a favorable safety, tolerability, and pharmacokinetics profile of REL-1017, consistent with results observed in the previously completed Phase 1 studies.For media inquiries, please contact relmada@fischtankpr.com.
What does Relmada Therapeutics, Inc specialize into ?
We are not able to find any specialities related to Relmada Therapeutics, Inc at the moment.
Who is the CEO of Relmada Therapeutics, Inc ?
We do not have the information about the CEO of Relmada Therapeutics, Inc. Our systems are trying to find it, we will update it as soon as we have it.
Try Mr. E's contact finder tool and fetch direct mobile numbers of decision-makers of all companies globally. Grow your sales now.
Free Trial with 5 contacts. No Credit Card Required. One-click Signup.